Investment Rating - The report maintains an "Outperform" rating for the company [6] Core Insights - The company's H1 2025 performance met expectations, with total revenue of 11.101 billion yuan (YoY +13%) and net profit attributable to shareholders of 3.603 billion yuan (YoY +63%) [6] - Vitamin prices declined in Q2, while the methionine market showed an upward trend, and the fine chemical platform continued to expand [6] - The company is progressing well with new material projects and is entering the pesticide market, enhancing its "Chemical+" and "Biological+" platforms [6] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 23.936 billion yuan, with a YoY growth rate of 10.8% [5] - Net profit attributable to shareholders is projected at 6.510 billion yuan for 2025, reflecting a YoY increase of 10.9% [5] - The company’s gross margin is expected to be 41.2% in 2025, with a return on equity (ROE) of 19.0% [5] - The PE ratios for 2025-2027 are estimated at 12X, 11X, and 9X respectively, indicating a high safety margin [6]

Key Insights - The report highlights the significant growth in the nutritional products sector, with New Hope Liuhe (002001.SZ) achieving a revenue of 11.101 billion yuan, a year-on-year increase of 12.76%, and a net profit of 3.603 billion yuan, up 63.46% [10] - The report emphasizes the robust performance of the amino acid market, particularly methionine, with prices rising to 22,200 yuan per ton, reflecting a year-to-date increase of 12.98% [11] - The report notes the steady performance of the vitamin A and E segments, with revenue of 2.085 billion yuan and a net profit of 1.209 billion yuan, maintaining a net profit margin of 58% despite recent price declines [12] Company Analysis - New Hope Liuhe's nutritional products segment accounted for 64.86% of total revenue, with a gross margin of 47.79%, an increase of 11.93 percentage points year-on-year [10] - The company has expanded its methionine production capacity to 460,000 tons per year, positioning it as the third-largest producer globally [11] - The vitamin segment's revenue is expected to remain stable, with recent price adjustments indicating limited further declines [12] Industry Trends - The real estate sector is experiencing a downturn, with a 6.5% year-on-year decline in sales volume and a 4.0% decrease in sales area as of July 2025 [22] - The average price of new residential properties has decreased by 2.6% year-on-year, indicating ongoing pressure in the housing market [23] - Recent policy relaxations in major cities like Beijing and Shanghai are expected to provide some support to the real estate market, although the overall outlook remains cautious [24] Financial Performance - The report indicates that Beike-W (02423.HK) achieved a revenue of 26 billion yuan in Q2 2025, a year-on-year increase of 11%, although net profit declined by 32% [28] - Yuexiu Property (00123.HK) reported a revenue of 47.6 billion yuan, a 34.6% increase, but a net profit decline of 25.2% due to lower gross margins [31] - Zhou Dasheng (002867.SZ) experienced a 43.29% drop in revenue to 4.597 billion yuan, while net profit remained relatively stable, reflecting a 1.27% decline [32] Market Outlook - The report suggests that the non-bank financial sector is poised for growth, driven by a shift in deposit behaviors and increased demand for risk assets [25] - The overall market is in a recovery phase, with expectations of a gradual improvement in economic conditions and investment opportunities in various sectors [26] - The report maintains a positive outlook for companies with strong fundamentals and innovative product offerings, particularly in the nutritional and financial sectors [13][26]

公募基金方面，本期较上一期持股增加的公募基金共计2个，包括华泰柏瑞沪深300ETF、易方达沪深 300ETF，持股增加占比达0.13%。本期较上一季度持股减少的公募基金共计3个，包括易方达沪深300医 药ETF、鹏华中证医药指数(LOF)A、医疗健康，持股减少占比小幅下跌。本期较上一季度新披露的公 募基金共计25个，主要包括融通深证100指数A/B、招商中证全指红利质量ETF、鹏华沪深300ETF、红 利ETF、南华丰汇混合A等。本期较上一季未再披露的公募基金共计87个，主要包括广发中证全指医药 卫生ETF、鹏华沪深300指数增强A、汇添富中证医药卫生ETF、华夏中证红利质量ETF、天弘中证医药 100A等。 2025年8月28日，新和成(002001.SZ)发布2025年半年度报告。截至2025年8月27日，共有78个机构投资 者披露持有新和成A股股份，合计持股量达19.30亿股，占新和成总股本的62.81%。其中，前十大机构 投资者包括新和成控股集团有限公司、香港中央结算有限公司、全国社保基金五零三组合、中国工商银 行股份有限公司-华泰柏瑞沪深300交易型开放式指数证券投资基金、上海重阳战略投资有限公司- ...

Group 1 - Xinhua Media achieved a net profit of 32.34 million yuan in the first half of 2025, a year-on-year increase of 9.29% [1] - Xinhua Media's operating income for the first half of 2025 was 631 million yuan, a year-on-year growth of 2.45% [1] - China Galaxy reported a net profit of 6.488 billion yuan, up 47.86% year-on-year, with an operating income of 137.47 billion yuan, a 37.71% increase [2] Group 2 - Lek Electric's net profit decreased by 29.01% to 428 million yuan, despite a slight revenue increase of 0.65% to 4.781 billion yuan [3] - Honghui Fruits and Vegetables reported a net profit of 6.9243 million yuan, down 44.82%, with revenue of 470 million yuan, up 7.86% [4] - Bull Group's net profit fell by 8% to 2.06 billion yuan, with a revenue decline of 2.6% to 8.168 billion yuan [5] Group 3 - Nanshan Aluminum achieved a net profit of 2.625 billion yuan, a year-on-year increase of 19.95%, with operating income of 17.274 billion yuan, up 10.25% [6] - Zhujiang Beer reported a net profit of 612 million yuan, a 22.51% increase, with revenue of 3.198 billion yuan, up 7.09% [8] - Baolong Technology's net profit decreased by 9.15% to 135 million yuan, with revenue growth of 24.06% to 3.95 billion yuan [10] Group 4 - Jindi Co. reported a net profit of 75.93 million yuan, a year-on-year increase of 32.86%, with operating income of 835 million yuan, up 40.57% [12] - China Vision Media turned a profit with a net profit of 19.9811 million yuan, compared to a loss of 18.4349 million yuan in the previous year, despite a revenue decline of 10.75% to 229 million yuan [14] - Botao Bio's net profit fell by 82.82% to 12.4024 million yuan, with revenue down 23.91% to 203 million yuan [16] Group 5 - Caitong Securities reported a net profit of 1.083 billion yuan, a year-on-year increase of 16.85%, with operating income of 2.959 billion yuan, down 2.19% [18] - Yili Group's net profit decreased by 4.39% to 7.2 billion yuan, with revenue growth of 3.49% to 61.777 billion yuan [19] - Springlight Technology achieved a net profit of 7.3787 million yuan, a year-on-year increase of 83.73%, with revenue of 251 million yuan, up 39.6% [20] Group 6 - China Haifeng reported a net profit of 94.5739 million yuan, a year-on-year increase of 25.48%, with operating income of 1.385 billion yuan, up 19.64% [21] - Zhongke Titanium White's net profit decreased by 14.83% to 259 million yuan, with revenue growth of 19.66% to 3.77 billion yuan [23] - Huasheng Tiancai turned a profit with a net profit of 14 million yuan, compared to a loss in the previous year, despite a revenue decline of 10.75% to 226 million yuan [25] Group 7 - Shen Zhou Cell reported a net loss of 33.7711 million yuan, with revenue down 25.50% to 972 million yuan [26] - Meihu Co. achieved a net profit of 101 million yuan, a year-on-year increase of 10.26%, with operating income of 1.075 billion yuan, up 10.74% [28] - Jifeng Technology plans to apply for a comprehensive credit of 170 million yuan to supplement working capital [29] Group 8 - Foton Motor reported a net profit of 777 million yuan, a year-on-year increase of 87.57%, with operating income of 30.371 billion yuan, up 26.71% [41] - BOE Technology achieved a net profit of 3.247 billion yuan, a year-on-year increase of 42.15%, with operating income of 110.278 billion yuan, up 8.45% [42] - CIMC reported a net profit of 1.278 billion yuan, a year-on-year increase of 47.63%, with operating income of 76.09 billion yuan, down 3.82% [43]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant year-on-year growth in revenue and net profit, indicating robust operational resilience and growth potential in its key business segments [1][2]. Financial Performance - The company achieved a revenue of 11.1 billion yuan in the first half of 2025, representing a year-on-year increase of 12.8%, and a net profit attributable to shareholders of 3.6 billion yuan, up 63.5% year-on-year [1]. - In Q2 2025, the company recorded a revenue of 5.66 billion yuan, a year-on-year increase of 5.9% and a quarter-on-quarter increase of 4.1%, with a net profit of 1.72 billion yuan, reflecting a year-on-year growth of 29.1% but a quarter-on-quarter decline of 8.3% [1]. Business Segments Performance - The nutrition products, flavor and fragrance, and new materials segments saw revenue growth of 7.78%, 9.35%, and 43.75% year-on-year, respectively [2]. - The gross margins for nutrition products and flavor and fragrance were 47.79% and 54.01%, showing increases of 11.93 percentage points and 4.32 percentage points year-on-year [2]. - The average prices for key products such as VA, VE, and methionine increased by 10.6%, 78.2%, and decreased by 0.8% year-on-year, respectively [2]. Future Growth Drivers - The company is expanding its methionine production capacity by 70,000 tons and has initiated trial production of an 180,000 tons/year liquid methionine project in collaboration with Sinopec [3]. - The new materials segment generated revenue of 1.04 billion yuan in the first half of 2025, with a significant year-on-year growth of 43.75% [3]. - The company plans to invest 10 billion yuan in a project to produce 500,000 tons of adiponitrile and 400,000 tons of nylon 66, with regulatory approvals already completed for the Tianjin nylon new materials project [3]. Profit Forecast and Valuation - The company has adjusted its net profit forecasts for 2025-2027 to 6.61 billion, 7.04 billion, and 8.10 billion yuan, with corresponding EPS of 2.15, 2.29, and 2.64 yuan [4]. - The current price corresponds to a PE ratio of 11.4, 10.7, and 9.3 for the years 2025, 2026, and 2027, respectively [4]. - The company is recognized as a global leader in nutrition products and flavor and fragrance, with strong internal growth drivers and an expanding product line, maintaining a "buy" rating [4].

Investment Rating - The report maintains an "Overweight" rating for the company [6][4]. Core Views - Despite a significant drop in vitamin prices in Q2 2025, the company's performance remains strong, driven by favorable product dynamics in methionine and steady growth in new materials and flavoring businesses [1][3]. - The increase in net profit for the first half of 2025 is primarily attributed to the robust market for vitamins A and E, with prices rising by 10% and 77% year-on-year, respectively [2]. - The company is expected to continue its growth trajectory in emerging fields such as animal nutrition, human nutrition, and high-end materials, with a positive outlook for future performance [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 11.1 billion RMB, a year-on-year increase of 13%, and a net profit of 3.6 billion RMB, up 63% year-on-year [1]. - Q2 2025 revenue was 5.7 billion RMB, reflecting a 6% year-on-year increase and a 4% quarter-on-quarter increase, with net profit of 1.7 billion RMB, up 29% year-on-year but down 8% quarter-on-quarter [1]. Segment Performance - The nutrition business generated revenue of 7.2 billion RMB in H1 2025, a 7.8% increase year-on-year, with a gross margin improvement of 11.9 percentage points to 47.8% [2]. - The flavoring business continued to grow, achieving revenue of 2.1 billion RMB, a 9.4% year-on-year increase, with a gross margin increase of 4.3 percentage points to 54% [2]. - The new materials segment reported revenue of 1.04 billion RMB, a significant year-on-year increase of 44% [2]. Profitability and Valuation - The report forecasts net profits for 2025-2027 to be 6.6 billion, 7.2 billion, and 8.0 billion RMB, respectively, with corresponding EPS of 2.14, 2.34, and 2.61 RMB [4]. - The target price has been adjusted to 27.82 RMB, based on a 13x PE ratio for 2025, reflecting an increase from the previous target of 23.65 RMB [4].

Core Insights - The report highlights the updated monthly interest rate timing model, which shows improved predictive accuracy with a success rate of 74% for the recent two years [12][14] - The company Atour (ATAT.O) has raised its full-year retail revenue guidance, with Q2 revenue growing by 37.4% year-on-year to 2.47 billion yuan, exceeding expectations [15][17] - Shenzhen International (00152.HK) reported a revenue of 6.67 billion yuan, a year-on-year increase of 0.9%, with a focus on logistics park transformation projects [18][16] Group 1: Interest Rate Timing Strategy - The updated model incorporates richer factor indicators and adjusts weightings for different types of indicators, enhancing predictive capabilities [14] - Three strategy applications have been designed: basic timing strategy, timing & treasury futures strategy, and timing & leverage strategy, all outperforming longer-duration benchmarks [14] - The timing & leverage strategy achieved a maximum annualized excess return of 128 basis points [14] Group 2: Atour (ATAT.O) Performance - Atour's Q2 performance exceeded expectations, with a net profit increase of 39.8% year-on-year to 425 million yuan [15][17] - The company opened 118 new hotels in Q2, maintaining its target of 500 new openings for the year [15][17] - Retail business GMV reached 1.144 billion yuan in Q2, a year-on-year growth of 84.6%, with online sales accounting for over 90% [15][17] Group 3: Shenzhen International (00152.HK) Insights - The company’s logistics park transformation and asset securitization strategies are expected to enhance earnings resilience [18][16] - For 2025-2027, net profit forecasts are 3.081 billion, 3.430 billion, and 3.925 billion HKD, with a dividend yield projected at 8.3%, 9.3%, and 10.6% respectively [18][16] - The logistics park business reported a revenue of 785 million HKD in H1 2025, a year-on-year increase of 5.4% [18][16] Group 4: Steel Industry Performance - Baosteel (600019) reported steady growth with high dividend maintenance, while Hualing Steel (000932) saw a significant increase in high-end product sales [20][24] - The steel industry is experiencing a shift towards high-end products, with companies like Zhongxin Special Steel (000708) maintaining stable performance [26] - The overall steel market is expected to benefit from reduced raw material costs and improved product structures, leading to enhanced profitability [24][26]

证券研究报告 | 2025年08月28日 风险提示：行业竞争加剧、产品价格下降、新项目投产进度低于预期等。 新和成（002001.SZ） 优于大市 营养品量价齐升，上半年业绩大幅增长 毛利率提升叠加费用率下降，上半年公司归母净利润实现高速增长。上半年， 公司实现营业收入 111.01 亿元，同比增长 12.76%；实现归母净利润 36.03 亿元，同比增长 63.46%；销售毛利率 45.89%，同比提升 8.78 pcts，销售净 利率 32.62%，同比提升 10.10 pcts，销售期间费用率 6.69%，同比下降 2.68%。 公司第二季度实现营业收入 56.61 亿元，同比提升 5.89%，环比提升 4.07%， 实现归母净利润 17.23 亿元，同比提升 29.12%，环比下降 8.32%，延续增长 态势。分业务看，营养品业务实现营业收入 72.00 亿元，同比增长 7.78%， 营收占比 64.86%，毛利率 47.79%，同比提升 11.93 pcts；香精香料业务实 现营业收入 21.05 亿元，同比增长 9.35%，营收占比 18.96%，毛利率 54.01%， 同比提升4.32 pcts ...

Core Insights - The company reported a revenue of 11.1 billion yuan for the first half of 2025, representing a year-on-year growth of 13%, with a net profit attributable to shareholders of 3.6 billion yuan, up 63% year-on-year [1] - In Q2 2025, the company achieved a revenue of 5.7 billion yuan, a 6% increase year-on-year and a 4% increase quarter-on-quarter, with a net profit of 1.7 billion yuan, reflecting a 29% year-on-year growth but an 8% decline quarter-on-quarter [1] Business Analysis - The nutrition and flavor segments showed positive revenue and profit growth, driving the company's strong performance. The nutrition segment generated 7.2 billion yuan in revenue, an 8% increase year-on-year, with a gross margin of 48%, up 12 percentage points year-on-year. The flavor segment reported revenue of 2.1 billion yuan, a 9% increase year-on-year, with a gross margin of 54%, up 4 percentage points year-on-year [2] - The company is actively seizing market opportunities in nutrition, new materials, and flavors while maintaining its market advantages in existing products. It is also promoting the market expansion of new products such as HA series and tryptophan [2] - Project construction is progressing steadily, with the company’s overseas expansion efforts advancing. The liquid methionine project in partnership with Sinopec is in trial production, and the Tianjin nylon new materials project has completed compliance approvals [2] - The company is enhancing its international digital layout, accelerating localization of sales and R&D overseas, and has established management systems for overseas operations, including pilot recruitment from overseas universities [2] Profit Forecast, Valuation, and Rating - The company is a leader in the vitamin sector, with the nutrition segment beginning to scale up and new projects continuing to advance, supporting long-term growth. The forecasted net profits attributable to shareholders for 2025-2027 are 6.598 billion, 7.073 billion, and 7.411 billion yuan, respectively, with corresponding PE ratios of 11.42, 10.65, and 10.17 times. The rating is maintained at "Buy" [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][10] Core Views - The company has shown a significant increase in net profit, with a year-on-year growth of 63.5% in Q2 2025, aligning with expectations. The company is steadily advancing new projects in liquid egg and nylon materials [6] - The revenue for H1 2025 reached 11.101 billion yuan, representing a 12.8% increase year-on-year, while the net profit attributable to the parent company was 3.603 billion yuan [6][9] - The company is expected to maintain strong growth momentum due to the development of new projects and products, with a projected net profit of 6.693 billion yuan for 2025 [6][10] Financial Performance Summary - For H1 2025, the company achieved revenue of 72.00 billion yuan in the nutrition segment, with a year-on-year growth of 7.78%, and a gross margin of 47.79% [7][12] - The new materials segment reported revenue of 10.38 billion yuan, reflecting a year-on-year increase of 43.75% [7] - The company's gross margin and net margin for H1 2025 were 45.89% and 32.62%, respectively, showing improvements of 8.78 and 10.1 percentage points year-on-year [7][9] Project Progress - The company has initiated trial production for its 180,000 tons/year liquid methionine project and completed compliance approvals for the Tianjin nylon new materials project [7][10] - The company is actively pursuing market opportunities in nutrition, new materials, and flavors while promoting the market expansion of new products such as HA series and tryptophan [7][10] Market Conditions - The average market prices for Vitamin A, Vitamin E, and solid methionine as of August 27, 2025, were 64.0, 65.5, and 22.6 yuan per kilogram, respectively, indicating significant year-on-year declines for Vitamin A and E [7][15] - The company’s profitability is supported by the recovery in Vitamin E prices and the full production capacity of solid methionine [7][10]